Earnings Scheduled For January 8, 2025 - Albertsons Companies (NYSE:ACI), AngioDynamics (NASDAQ:ANGO)

Times Union

Lean Left

Factuality

Ownership

AngioDynamics hopes NanoKnife will become go-to prostate cancer treatment

Latham company recently received FDA approval to use its NanoKnife technology for minimally-invasive prostate cancer treatment that has shown promise.

Benzinga

Center

Factuality

Ownership

Earnings Scheduled For January 8, 2025 - Albertsons Companies (NYSE:ACI), AngioDynamics (NASDAQ:ANGO)

watchlistnews.com

Factuality

Ownership

AngioDynamics (ANGO) to Host NanoKnife Investor Event

AngioDynamics, Inc. (“AngioDynamics”) is set to host the virtual NanoKnife Irreversible Electroporation (IRE) Prostate Investor Event on January 8, 2025. The company’s presentation slides, filed as Exhibit 99.1 with the Securities and Exchange Commission on the same date, provide insights into AngioDynamics’ anticipated future financial standing, operational outcomes, strategic directives, and growth pursuits. The presentation […]